A Phase 2 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis

Inclusion Criteria

• •Must be 18 Years to 65 Years, both male and female.
• •BMI ≥18 kg/m\^2 and ≤32 kg/m\^2 ，and male weight ≥50 kg, female weight ≥45 kg during the screening.
• •Chronic plaque psoriasis (PSO) for at least 6 months prior to the randomizationas as determined by the investigator..
• •Psoriasis Area Severity Index (PASI) \>=12 and body surface area (BSA) affected by PSO \>=10% and Static Physician Global Assessment (sPGA) score \>=3.
• •According to the judgment of the investigator, the subject needs to receive systemic treatment and / or phototherapy (including subjects who have used local treatment, and / or phototherapy, and / or poor control of previous systemic treatment).
• •Subject must be able to understand and comply with the requirements of the study. and must participate voluntarily and sign the written informed consent.